Time filter

Source Type

Shurygin A.A.,Perm State Academy Of Medicine Named After Academy Ea Vagner | Lvova I.I.,Perm State Academy Of Medicine Named After Academy Ea Vagner | Deryusheva A.V.,Perm State Academy Of Medicine Named After Academy Ea Vagner | Varankina A.A.,Perm State Academy Of Medicine Named After Academy Ea Vagner | Legotina N.S.,Perm State Academy Of Medicine Named After Academy Ea Vagner
Life Science Journal | Year: 2014

The rationale for immunotherapy with interferon -α-2β (VIFERON® 3 million IU and 1 million IU in suppositories) in the treatment of pulmonary tuberculosis in adolescents was the prevalence of clinical and laboratory markers of secondary immune deficiency identified complex examination 62 hospitalized patients: more than two chronic diseases (75,8%); recurrent infection caused by the herpes simplex viruses (HSV 1,2) (54.8%), on the background of combined serological HSV 1,2activation (90.3%) and cytomegalovirus (CMV) infection (93.6%); the decrease in the absolute number of leukocytes and the low levels orabsence of interferon -alpha (29.0%) and interferon - gamma (77.4%). The efficiency and safety of the treatment with VIFERON® proved on the basis of significant positive clinical and laboratory criteria: an increase in body weight in 84.6% of adolescents; reducing the frequency of arrhythmias; increase in absolute lymphocyte count (46.1%); decreased serological activation HSV 1,2 (30.8%) and CMV (61.5%); increase in the amount of interferon -alpha (61.5%) and interferon - gamma (61.5%);the absence of the intolerance 3 times reduction in the undesirable effects of chemotherapy.

Loading Perm State Academy Of Medicine Named After Academy Ea Vagner collaborators
Loading Perm State Academy Of Medicine Named After Academy Ea Vagner collaborators